Tonix Pharmaceuticals releases positive results from Proof-Of-Concept Study on TNX-102 SL
Tonix Pharmaceuticals CEO Dr Seth Lederman joined Steve Darling from Proactive to share significant news regarding the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL 5.6 mg for the management...